BioLargo (BLGO) AI Stock Analysis

• Market Cap: $56.16M
• Dividend Yield: N/A
• Average Volume (3M): 570.01K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.33
• Revenue Growth: -41.57%
• EPS Growth: -345.83%
• Country: US
• Employees: 40
• Sector: Basic Materials
• Sector Strength: 58
• Industry: Chemicals
• EPS (TTM): -0.02
• Shares Outstanding: 313,762,660
• 10 Day Avg. Volume: 632,227
• 30 Day Avg. Volume: 570,010
• PEG Ratio: 0.69
• Price to Book (P/B): 6.40
• Price to Sales (P/S): 3.19
• P/FCF Ratio: -12.75
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 4.93
• Enterprise Value/Gross Profit: 10.58
• Enterprise Value/Ebitda: -4.68
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 48 Neutral
• Price Target: $0.19 ▼(-1.58% Downside)

The score is primarily constrained by deteriorating financial performance: declining TTM revenue, widening losses, and accelerating cash burn despite manageable leverage. Technical indicators are moderately supportive in the near term (positive MACD; price above key short/medium DMAs), but valuation remains pressured by unprofitability, and the latest earnings call balances promising technology developments against significant Pooph-related revenue/credit issues and legal risk.

Positive Factors

Revenue Growth

Strong revenue growth over recent years indicates successful market penetration and demand for BioLargo's environmental technologies.

Technological Advancements

Third-party validation of battery technology enhances credibility and opens potential new revenue streams through industrial applications.

Strategic Partnerships

Strategic partnerships, like with Clyra Medical, expand BioLargo's market reach and potential revenue, supporting long-term growth.

Negative Factors

Legal Disputes

Ongoing legal disputes with Pooph create financial uncertainty and distract management from core business operations.

Negative Cash Flow

Persistent negative cash flow indicates operational inefficiencies and reliance on external financing, posing long-term financial risks.

Revenue Decline

Significant revenue decline due to Pooph's credit loss suggests vulnerability in revenue streams and highlights dependency on key clients.

BioLargo Business Overview & Revenue Model

Company Description

BioLargo, Inc. invents, develops, and commercializes various platform technologies. The company's technologies solve challenging environmental problems comprising per- and polyfluoroalkyl substances contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. It holds various issued patents, maintains a pipeline of products, and provides full-service environmental engineering services. The company's products include Advanced Oxidation system, a water treatment device that generates a series of oxidative and energetic species of iodine and other molecules; Aqueous Electrostatic Concentrator, a water treatment system that removes per- and poly-fluoroalkyl substances from water; CupriDyne Clean industrial products, which reduce and eliminate tough odors and volatile organic compounds in various industrial settings; and advanced wound care products. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.

How the Company Makes Money

BioLargo generates revenue through multiple streams, primarily from the sale of its proprietary environmental technologies and products. Key revenue sources include direct sales of its AOS system and related services to industrial and municipal clients, as well as licensing agreements with partners for the use of its technologies. The company also engages in research and development contracts, providing tailored solutions that meet specific client needs. Strategic partnerships with organizations and governmental agencies enhance its market reach and credibility, contributing to its potential earnings. Additionally, BioLargo explores opportunities for joint ventures and collaborations that can further expand its product offerings and customer base.

BioLargo Financial Statement Overview

Summary

Despite prior multi-year revenue scaling and steady gross margins (~44–50%), the latest TTM shows a sharp sales decline (-23.1%), materially wider operating losses (operating margin roughly -49%), and significantly higher cash burn (operating cash flow about -$8.6M). Leverage is relatively low (debt-to-equity ~0.23 TTM), but persistent losses and negative free cash flow remain the core risk.

Income Statement

Revenue scaled meaningfully from 2020–2024, but the latest TTM (Trailing-Twelve-Months) shows a sharp decline in sales (down 23.1%), raising questions on near-term momentum. Gross margin remains fairly solid and consistent (~44–50%), suggesting the core offering can generate decent product-level profitability. However, the company is still deeply unprofitable: operating losses widened materially in TTM (operating margin roughly -49%) versus 2024 (about -24%), and net losses also expanded, indicating costs are not scaling with revenue and profitability remains a key weakness.

Balance Sheet

Leverage appears manageable with low-to-moderate debt relative to equity (debt-to-equity around 0.23 in TTM and ~0.29 in 2024), which reduces balance sheet risk versus highly levered peers. That said, the company is generating large losses, reflected in very weak returns on equity (negative across all periods, and significantly worse in TTM). Equity provides some cushion, but ongoing losses can pressure that cushion over time if not offset by improved profitability or external capital.

Cash Flow

Cash generation is a major concern: operating cash flow and free cash flow are consistently negative across the entire period. In TTM (Trailing-Twelve-Months), operating cash burn accelerated to about -$8.6M (worse than -$3.2M in 2024), and free cash flow is similarly negative, implying continued reliance on funding rather than self-sustaining operations. While free cash flow improved versus the prior period on a growth basis in TTM, the absolute burn rate remains high and is the key risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	10.81M	17.78M	12.23M	5.88M	2.53M	2.43M
Gross Profit	5.03M	7.85M	6.15M	2.86M	1.10M	1.23M
EBITDA	-11.37M	-4.06M	-4.19M	-5.10M	-6.70M	-7.83M
Net Income	-9.84M	-2.40M	-3.50M	-4.50M	-7.38M	-10.47M
Balance Sheet
Total Assets	9.13M	10.51M	8.21M	4.86M	3.02M	4.94M
Cash, Cash Equivalents and Short-Term Investments	4.55M	3.55M	3.54M	1.85M	962.00K	716.00K
Total Debt	1.49M	2.55M	1.70M	1.47M	1.13M	2.67M
Total Liabilities	2.46M	4.46M	4.00M	2.85M	2.09M	5.18M
Stockholders Equity	6.58M	8.85M	6.84M	4.88M	4.65M	3.86M
Cash Flow
Free Cash Flow	-8.60M	-4.44M	-2.84M	-3.03M	-3.97M	-4.18M
Operating Cash Flow	-8.62M	-3.21M	-2.37M	-2.76M	-3.94M	-4.15M
Investing Cash Flow	391.00K	-1.32M	-478.00K	-271.00K	-34.00K	-123.00K
Financing Cash Flow	8.86M	4.44M	4.66M	3.96M	4.23M	4.34M

BioLargo Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.19
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BLGO, the sentiment is Negative. The current price of 0.19 is above the 20-day moving average (MA) of 0.18, above the 50-day MA of 0.18, and below the 200-day MA of 0.19, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 47.73 is Neutral, neither overbought nor oversold. The STOCH value of 60.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BLGO.

BioLargo Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$10.43B	7.12	-0.05%	2.87%	2.86%	-36.73%
ASIX	58 Neutral	$425.53M	8.24	6.62%	3.81%	-5.05%	35.01%
RYAM	56 Neutral	$519.96M	-1.27	-78.11%	―	-9.75%	-386.63%
FF	51 Neutral	$144.11M	―	-18.09%	7.12%	-49.82%	-195.74%
TROX	49 Neutral	$960.83M	-3.11	-18.65%	8.27%	-7.81%	-334.15%
BLGO	48 Neutral	$56.16M	-5.55	-129.84%	―	-41.57%	-345.83%
ORGN	40 Underperform	$29.34M	-0.39	-21.13%	―	-28.47%	16.83%

BioLargo Corporate Events

BioLargo Officers Convert Salary to Common Stock

On November 14, 2025, BioLargo Inc. announced that two of its officers converted $99,901 of unpaid salary and unreimbursed business expenses into 624,383 shares of common stock at a price of $0.16 per share. These shares are subject to a Lock-Up Agreement, restricting their sale until the company achieves certain financial milestones, such as reporting gross revenue of at least $40 million, reaching a market capitalization of $300 million, or undergoing a change in control.

BioLargo to Present Investor Webcast on Nov 14

BioLargo, Inc. announced that it will present a slide deck during an investor webcast scheduled for November 14, 2025. The presentation is part of the company’s ongoing efforts to engage with investors and provide updates on its operations, although the information shared will not be incorporated into any SEC filings. This move reflects BioLargo’s strategy to maintain transparency and communication with stakeholders while managing regulatory obligations.

BioLargo Participates in LD Micro Main Event XIX

BioLargo, Inc. announced its participation in the LD Micro Main Event XIX, held on October 20 at the Hotel del Coronado in San Diego, California. The company presented slides during this event, although the information shared is not considered filed with the SEC and is not subject to certain liabilities under the Securities Exchange Act of 1934.